Similarly, Sakai et al. [37] reported acquired resistance to cisplatin and PARP-is in BRCA2 breast and pancreatic cancer cell lines through acquisition of secondary genetic events restoring wild-type BRCA2 function. The gene discussed is BRCA2; the disease is familial pancreatic carcinoma.